Welcome to our dedicated page for TC Biopharm (Holdings) Plc news (Ticker: TCBP), a resource for investors and traders seeking the latest updates and insights on TC Biopharm (Holdings) Plc stock.
TC BioPharm (Holdings) PLC (NASDAQ: TCBP) is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative immunotherapy products. The company leverages its proprietary allogeneic gamma-delta T (GD-T) cell platform to create novel therapies aimed at treating cancer and viral infections.
Gamma-delta T cells are unique immune cells that possess characteristics of both the innate and adaptive immune systems, enabling them to distinguish between healthy and diseased tissues. TC BioPharm's approach uses these cells to develop effective treatments for various cancers, including both liquid and solid tumors.
Notable achievements include the initiation of phase 2b/3 pivotal trials for OmnImmune® in the treatment of acute myeloid leukemia (AML) using their proprietary allogeneic CryoTC technology, which allows for the distribution of frozen cell products to clinics worldwide. The company also maintains a robust pipeline targeting solid tumors and has built a significant intellectual property portfolio.
Recent developments highlight TC BioPharm's dynamic progress:
- March 1, 2024: CEO Bryan Kobel featured on 'The Big Biz Show,' discussing the company's ongoing advancements.
- March 18, 2024: An institutional investor exercised warrants resulting in a net cash infusion of $1.17M, strengthening the company’s financial position.
- March 19, 2024: The company adjourned its General Meeting to gather additional information for a shareholder vote.
- April 2, 2024: Announcement of a new streamlined manufacturing process to increase patient treatment capacity and reduce costs by 85%.
- April 4, 2024: Execution of a non-binding letter of intent to acquire assets focused on CAR-NK cell therapies, enhancing their cancer treatment capabilities.
- May 6, 2024: Agreement for the immediate exercise of certain warrants, raising approximately £3.1M for clinical trials and operations.
- May 6, 2024: Announcement of a second letter of intent to acquire a company developing CAR-T therapies for solid tumors and autoimmune diseases.
- May 15, 2024: Launch of a compassionate use program in the UK for TCB-008, providing new treatment options for patients ineligible for clinical trials.
TC BioPharm continues to focus on expanding its therapeutic platform, leveraging strategic partnerships, and advancing its clinical trials, all while upholding its commitment to improving patient outcomes.
TC BioPharm (NASDAQ: TCBP) has announced the dosing of the sixth patient in its ACHIEVE UK clinical trial for acute myeloid leukemia (AML) on July 16, 2024. This marks the first patient treated with a higher dose of TCB-008 following an amendment approved by the MHRA in February 2024. The trial, now in Phase II, aims to evaluate the efficacy of TCB-008 in patients with AML or MDS/AML who have relapsed or refractory disease.
The study consists of two cohorts: Cohort A for relapsed/refractory patients and Cohort B for patients with detectable residual disease after remission. The new dosage contains up to 230 million cells per dose, increased from the previous 35 million. Eligible patients may receive up to four doses, totaling approximately 1 billion cells. TC BioPharm expects to dose up to 10 more patients in 2024 and plans to open an additional clinical trial site in Q3.
TC BioPharm (NASDAQ: TCBP) announced the launch of a compassionate use program for its lead therapeutic, TCB008. This program allows access to TCB008 for patients in the UK who cannot be treated with available licensed treatments. Compassionate use involves prescribing unlicensed medicinal products in specific clinical scenarios. Patients must meet entry criteria to ensure safety and data integrity. Regulatory approval is required for any market use of these products. The program provides treatment options for patients not eligible for experimental treatments in clinical trials. CEO Bryan Kobel emphasized the importance of patient needs, quality of life, and the potential to expand data and use cases for TCB008.
TC BioPharm (Holdings) plc announced the exercise of warrants for £3.1 million gross proceeds. The Company entered into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase 1,750,000 of the Company's American Depositary Shares. The gross proceeds are expected to be approximately £3.1 million. In return for the exercise of the warrants, the Company will issue new unregistered warrants to purchase 3,500,000 shares of common stock. The offering is expected to close on May 8, 2024. The net proceeds will be used to support an upcoming clinical trial on Acute Myeloid Leukemia.
TC BioPharm (NASDAQ: TCBP) announced the execution of a non-binding letter of intent to acquire a biotechnology company focusing on CAR-T therapies for refractory cancers and solid tumors. The acquisition target has proven the therapeutic potential of its lead CAR-T candidate for various solid tumors and is also developing a novel allogeneic CAR-T for autoimmune diseases. The potential acquisition aims to expand TC BioPharm's therapeutic platform and bring synergies in CAR development expertise, providing multiple shots on goal for the treatment of various indications.
FAQ
What does TC BioPharm (Holdings) PLC specialize in?
What are gamma-delta T cells?
What is OmnImmune®?
How does TC BioPharm's CryoTC technology work?
What recent financial milestones has TC BioPharm achieved?
What new manufacturing initiatives has TC BioPharm announced?
What is TC BioPharm's compassionate use program?
What are the company's latest strategic acquisitions?
Where can I watch the CEO's interview on 'The Big Biz Show'?
What is TC BioPharm's position in the biopharmaceutical industry?
